How to Save on GLP-1 Medications: A Guide to Navigating Costs and Insurance
For many Americans, GLP-1 medications have been transformative for weight management and metabolic health. However, the financial burden often outweighs the clinical benefits. While it’s widely reported that semaglutide and tirzepatide can cost around $1,000 per month, that “sticker price” at a local pharmacy isn’t the only option available.
Approximately 1 in 8 American adults have tried a GLP-1 medication, but a significant number of users discontinue treatment when out-of-pocket costs become unsustainable. Whether you’re facing an insurance denial or paying cash, there are strategic ways to lower your monthly expenses.
- Direct-to-Consumer: Manufacturers now offer lower prices via their own websites and specific retail partners.
- Persistence Pays: Insurance rejections can often be overturned through repeated appeals and new prior authorizations.
- Clinical Indications: Coverage may vary depending on whether the drug is prescribed for weight loss, diabetes, or other FDA-approved conditions.
Direct-to-Consumer Pricing and Manufacturer Options
Drugmakers have recently introduced alternative avenues to bypass traditional pharmacy markups, making these medications more accessible for those without comprehensive insurance coverage.
Eli Lilly (Tirzepatide and Foundayo)
Lilly, the manufacturer of Mounjaro and Zepbound, now offers these medications for between $349 and $499 per month. These prices are available when purchasing through the company’s website or at Walmart.
Lilly offers an FDA-approved GLP-1 pill called Foundayo. Depending on the dosage, Foundayo costs approximately $149 to $299 per month without insurance via Lilly’s direct-to-consumer website.
Novo Nordisk (Semaglutide)
Novo Nordisk, the maker of Ozempic and Wegovy, has implemented similar pricing structures. Most doses of their weight loss and diabetes pills are available for $149 to $299 per month, while their injectable versions range from $349 to $499 per month. These rates can be accessed through the manufacturer’s website or partners such as Costco and WW.
Note on Administration: Patients should be aware that these lower-cost options may sometimes be administered via a vial and syringe or in pill form, rather than the more convenient prefilled injector pens.
Overcoming Insurance Denials
An initial insurance rejection is not necessarily the final word. Navigating the “code” of insurance companies requires persistence and specific documentation.
The Power of the Appeal
Many patients have successfully regained coverage by refusing to accept an initial denial. In some cases, the solution is as simple as requesting a new prior authorization—a formal request your doctor submits to the insurer to prove the treatment is medically necessary. Even if a prior authorization was already on file, submitting a fresh request can sometimes trigger an approval.
Switching Prescribing Diagnoses
Insurance coverage often depends on the “indication” (the medical reason) for the prescription. While an insurer might deny a GLP-1 for weight loss, they may cover the same drug for other FDA-approved uses.
According to Dr. Supriya Rao, an obesity physician and director of medical weight loss at Lowell General Hospital, GLP-1s are approved for more than just weight loss, including:
- Type 2 diabetes
- Cardiovascular risk reduction
- Stroke prevention in specific populations
- Metabolic dysfunction-associated steatohepatitis (MASH)
Dr. Brianna Johnson-Rabbett, an endocrinologist with Nebraska Medicine and director of the American Board of Obesity Medicine, notes that specific combinations can change coverage outcomes. For example, Wegovy may be prescribed under the indication of established cardiovascular disease and obesity, while Zepbound may be prescribed for those with obesity and moderate to severe obstructive sleep apnea.
Disclaimer: Switching a diagnosis is not a guarantee of coverage, as insurers may still deny a medication even if FDA indications are met.
Additional Savings Strategies
Beyond direct pricing and insurance appeals, patients can explore these temporary relief options:
- Savings Cards and Coupons: Manufacturers often provide coupons that significantly lower out-of-pocket costs for up to one year. However, these are not permanent and have strict eligibility requirements.
- Government-Run Platforms: In November 2025, manufacturers announced that even lower prices would be available in the coming years for drugs purchased through a government-run website.
Frequently Asked Questions
Q: Will I get the same medication if I buy it directly from the manufacturer?
A: Yes, you are receiving the FDA-approved medication, though the delivery method (pill or vial vs. Pen) may differ depending on the price point.
Q: What should I do if my insurance says my medication is “no longer covered”?
A: Contact your doctor to discuss a new prior authorization or check if you meet the criteria for other FDA-approved indications, such as sleep apnea or cardiovascular risk reduction.
Q: Are manufacturer coupons available to everyone?
A: No. Savings cards typically have income limits or insurance requirements and usually expire after a set period.
Looking Ahead
The landscape of GLP-1 affordability is shifting rapidly. With the move toward direct-to-consumer sales and the upcoming implementation of government-run purchasing platforms, the gap between clinical need and financial access is beginning to close. Patients are encouraged to stay in close communication with their healthcare providers to ensure they are utilizing the most current and cost-effective pathways to treatment.
Keep reading